Exelixis, Inc. (NASDAQ:EXEL) announced that the European Medicines Agency’s Committee for Medical Products for Human Use (CHMP) has adopted a positive opinion of the …
Exelixis, Inc. (NASDAQ:EXEL) announced three high-level appointments as the company prepares for the potential commercialization of its lead compound, cabozantinib, for the treatment of …
William Blair analyst John Sonnier came out with his views on Exelixis, Inc. (NASDAQ:EXEL), after hosting meetings with the company’s management.
William Blair’s healthcare analyst John Sonnier weighed in today with a few insights on Exelixis, Inc. (NASDAQ:EXEL), after the biopharmaceutical company announced that the the Swiss authority which …
Seadrill Ltd (NYSE:SDRL) is up 3.08% in pre-market trading to $6.
William Blair analysts John Sonnier and Y Katherine Xu issued a note to investors on August 26 highlighting their best investment ideas in …
Exelixis, Inc. (NASDAQ:EXEL) announced that Swissmedic, the Swiss licensing and supervisory authority of Switzerland, has approved cobimetinib for use in combination with vemurafenib as …
Exelixis, Inc. (NASDAQ:EXEL) announced that data from clinical trials of cabozantinib and cobimetinib will be the subject of three presentations at the European Cancer …
Exelixis, Inc. (NASDAQ:EXEL) announced the U.
Exelixis, Inc. (NASDAQ:EXEL) reported financial results for the second quarter of 2015 and provided an update on progress toward delivering upon its key 2015 …
